triple negative breast cancer

[Cancer Discovery] Scientists identified mechanisms of TNBC resistance to Sacituzumab Govitecan through RNA and whole-exome sequencing of pre-treatment and post-progression specimens.

[Cancer Research] Researchers identified decaprenyl diphosphate synthase subunit 1 (PDSS1) as an essential gene for TNBC metastasis. PDSS1 expression was significantly upregulated in TNBC tissues compared to adjacent normal tissues and was positively associated with poor survival among TNBC patients.

[Advanced Science] Lysine acetyltransferase 6A (KAT6A)-acetylated H3K23-mediated recruitment of tripartite motif-containing 24–SMAD3 complex to chromatin increased SMAD3 activation and immune response-related cytokine expression, leading to enhanced breast cancer stem-like cell stemness, myeloid-derived suppressor cell recruitment, and TNBC metastasis.

[Carrick Therapeutics] Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic TNBC.

[Molecular and Cellular Biology] Circular RNA circ-ERBB2 knockdown constrained TNBC growth in vivo and reduced Warburg effect, accelerated apoptosis, repressed proliferation, migration, and invasion of TNBC cells in vitro.

[Nature Communications] ICAM1 expression increased by 200-fold in the lung metastases of three TNBC patient-derived xenografts, and its depletion abrogated lung colonization of TNBC cells by inhibiting homotypic tumor cell-tumor cell cluster formation.